6 July 2011
Vantia today announced that it has raised £4 Million ($6.5 million) to fund clinical development of its lead compounds.
9 June 2010
Vantia today announced that it has appointed Andrew Crockett to the position of Chief Executive
26 March 2010
Vantia reveals structure of its novel small molecule treatment for dysmenorrhoea, VA111913,
at the ACS National Meeting in San Francisco, USA.
2 February 2010
Vantia's lead candidate VA106483 enters Phase IIb trial for nocturia.
7 December 2009
Vantia is listed in the British Venture Capital Association's HOT Talent Handbook, a rollcall of some of Britain's
most exciting young companies and a celebration of the best and the brightest plying their trade in the pursuit of invention
6 October 2009
Vantia's lead candidate VA111913 enters Phase II proof-of-concept trial in dysmenorrhoea.
26 August 2009
Vantia appoints Andrew Crockett as Vice President Business Development.
29 June 2009
Vantia's lead candidate VA106483 demonstrates positive anti-diuretic effect
in Phase IIa trial in nocturia.
21 April 2009
Vantia appoints Rachel Morten as Head of Regulatory Affairs.
24 March 2009
Vantia's pipeline continues to mature - VA106483 completes Phase IIa trial and VA111913 completes Phase I dosing.
26 November 2008
Jim Phillips, CEO of Vantia Ltd, talks to BioCentury about Vantia's rapid progress.
3 November 2008
Vantia progresses clinical development of its lead drug candidates - VA106483 starts Phase II and VA111913
enters clinic, VA118020 in preclinical development.
20 October 2008
An article titled "Could this pill cure
the agony of severe period pains?", describing the symptoms of dysmenorrhoea and Vantia's clinical trial
of VA111913, appeared in Daily Mail Online.
19 March 2008
New UK R&D company Vantia, launched with backing from
MVM Life Science Partners, SV Life Sciences and Novo A/S.
Adobe Reader may be required to view PDF files - if you need to install Adobe Reader please